3,5-dimethylaniline
structure in first source
Also Known As:
3,5-DMA cpd
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Skipper, Paul L:
3 articles
(05/2015 - 11/2007)
|
| 2. | Tannenbaum, Steven R:
3 articles
(05/2015 - 11/2007)
|
| 3. | Chao, Ming-Wei:
2 articles
(05/2015 - 09/2014)
|
| 4. | Trudel, Laura J:
2 articles
(05/2015 - 09/2014)
|
| 5. | Tseng, Chia-Yi:
2 articles
(05/2015 - 09/2014)
|
| 6. | Wogan, Gerald N:
2 articles
(05/2015 - 09/2014)
|
| 7. | Ye, Wenjie:
2 articles
(05/2015 - 09/2014)
|
| 8. | Erkekoglu, Pınar:
1 article
(05/2015)
|
| 9. | Erkekoglu, Pinar:
1 article
(09/2014)
|
| 10. | Cui, Liang:
1 article
(11/2007)
|
Related Diseases
| 1. | Urinary Bladder Neoplasms (Bladder Cancer)
09/01/2014
- " Epidemiological studies have demonstrated extensive human exposure to the monocyclic aromatic amines, particularly to 3,5-dimethylaniline, and found an association between exposure to these compounds and risk for bladder cancer. " 05/01/2015
- " Exposure to monocyclic aromatic alkylanilines (MAAs), namely 2,6-dimethylaniline (2,6-DMA), 3,5-dimethylaniline (3,5-DMA) and 3-ethylaniline (3-EA), was significantly and independently associated with bladder cancer incidence. " 11/01/2007
- " Although monocyclic aromatic amines are generally regarded as weak carcinogens, a recent epidemiologic study of bladder cancer found that the arylamine 3,5-dimethylaniline (3,5-DMA) may play a significant role in the etiology of this disease in man. "
|
|
Related Drugs and Biologics